Procter & Gamble Health share news, announcements and annual reports
NSE: PGHLBSE: 500126Pharmaceuticals & BiotechnologySmall Cap
Procter & Gamble Health Limited · Formerly Merck · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jan 1982 on BSE, Apr 1996 on NSE
Last close ₹5,670.50up ₹157.00 (2.85%)BSE ₹5,684.40
Share price at the NSE close on 30 Oct 2026. Previous close ₹5,513.50.
30 Oct: open ₹5,501.50, high ₹5,731.00, low ₹5,442.50
52-week range of traded prices to 30 Oct 2026
₹4,707.00Low, 6 Apr 2026₹6,975.00High, 15 Jul 2026
- Next results date: the board meets on 2 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹9,413 Cr585th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 26.37
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 17.94
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 3.62%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 67.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 84.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 13,61957.6% delivered
Procter & Gamble Health board and management
69 filed, newest first. Page 2 of 2.
Nov 2018
Mar 2018
27 Mar · Management
Dec 2017
Apr 2017
Dec 2016
Oct 2016
May 2015
Mar 2015
Jan 2015
Oct 2012
8 Oct · Management
Upon attaining superannuation, Mr. R L Shenoy has resigned from the office of director and whole time director of the Company with effect from September 30, 2012. The Board of Directors of the Company at its ensuing meeting on October 22, 2012 will consider the appointment of an additional director and executive director in place of Mr. Shenoy.
Jul 2012
28 Jul · Management
Company has appointed Dr. Claus-Dieter Boedecker as an additional director and Managing Director of the Company w.e.f August 01, 2012 in place of Dr. Marek Dziki, present Managing Director of the Company, whose term is expiring on July 31, 2012. As such Dr. Marek Dizki will cease to be a director and Managing Director of the Company with effect from July 31, 2012.
May 2012
22 May · Management
Mr H. U. Shenoy, Company Secretary of the Company has resigned w.e.f. May 11, 2012.
Apr 2011
25 Apr · Management
Mr. K. Shivkumar, Director has resigned as a Director from the Board of Director of Merck Limited w.e.f. May 24, 2011.
Nov 2010
18 Nov · Management
At the Meeting of the Board of Directors held on October 20, 2010 Mr Timothy Kneen has been appointed as a Non - Executive director in place of Mr. Ralph Antonius Zaat who has resigned with effect from October 20, 2010.
Mar 2010
30 Mar · Management
At the Meeting of the Board of Directors held on March 29, 2010, Mr. Pramod Pimplikar, VP - Technical Operations of the Company has been appointed as an additional director with effect from April 01, 2010.
Jul 2009
21 Jul · Management
At the Meeting of the Board of Directors held on July 20, 2009 Mr. Ralph Antonius Zaat has been appointed as a Director in place of Dr. Hans Hermansson.
Mar 2009
3 Mar · Management
At the Meeting of the Board of Directors held on February 26, 2009, the Board noted the resignation of Mr. A. Bhattacharjee as a Director, with effect from January 01, 2009.
Oct 2007
5 Oct · Management
E.Merck (India) Ltd has informed the Exchange that "Dr.J.Sombroek, Non Executive Director of the Company and Member of Audit Committee has resigned and ceased to be a Director and Member of Audit Committee with effect from 24th September,2007".
Jul 2007
16 Jul · Management
E.Merck (India) Ltd has informed the Exchange on July 16, 2007 that : "At the meeting of the Board of Directors held today Mr. A. Bhattacharjee has been appointed as an additional Director".